Emmaus Life Sciences, Inc. (EMMA)
| Market Cap | 21.20M |
| Revenue (ttm) | 18.51M |
| Net Income (ttm) | -9.07M |
| Shares Out | 49.31M |
| EPS (ttm) | -0.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,701 |
| Open | 0.420 |
| Previous Close | 0.370 |
| Day's Range | 0.420 - 0.600 |
| 52-Week Range | 0.250 - 4.000 |
| Beta | 0.94 |
| Analysts | Buy |
| Price Target | 4.59 (+967.4%) |
| Earnings Date | n/a |
About EMMA
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an a... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for EMMA stock is "Buy." The 12-month stock price forecast is 4.59, which is an increase of 967.44% from the latest price.
News
Emmaus Life Sciences Reports Q1 2022 Financial Results and Provides Business Update
TORRANCE, Calif. , May 13, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported ...
Emmaus Life Sciences to Present at Investor Conferences in May
TORRANCE, Calif. , April 26, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today annou...
Emmaus Life Sciences Presented Positive Real-World Data on the Efficacy of Endari® in Preventing Acute Complications ...
Sickle Cell Patients Treated With Endari ® had Statistically Significantly Fewer Vaso-Occlusive Events and Hospitalizations Through 72 Weeks Follow-up, Versus Baseline Adverse Events Among These Patien...
Emmaus Life Sciences Reports 2021 Financial Results and Provides Business Update
TORRANCE, Calif. , March 31, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reporte...
Emmaus Life Sciences Announces Endari® To Be Added to the Florida Medicaid Preferred Drug List
Florida Joins Other States in Eliminating the Need for Prior Authorization for Medicaid Patients TORRANCE, Calif. , March 29, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in t...
Emmaus Life Sciences Receives U.A.E. Marketing Authorization for Endari®
TORRANCE, Calif. , March 23, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA) a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announce...
Emmaus Life Sciences' Real World Data on Endari® Accepted for E-Poster at the 62nd Annual Scientific Meeting of the B...
TORRANCE, Calif., March 4, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced...
Insiders Buying These 3 Penny Stocks
Asian stock markets slumped on Tuesday amid escalating crisis in Russia and Ukraine. Investors, meanwhile, focused on some notable insider trades.
Emmaus Life Sciences to Present at the H.C. Wainwright BioConnect Conference
TORRANCE, Calif., Jan. 4, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced ...
Emmaus Life Sciences Presents Positive Transfusion Data from a Post-Hoc Analysis of its Phase 3 Clinical Study of End...
TORRANCE, Calif., Dec. 14, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced...
Emmaus Life Sciences to Webcast Live at Life Sciences Investor Forum on December 16th
TORRANCE, Calif., Dec. 9, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced ...
Emmaus Life Sciences' Data on Endari® Accepted for Poster Presentation at the 63rd American Society of Hematology Ann...
TORRANCE Calif., Dec. 6, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced t...
Emmaus Life Sciences Reports Third Quarter Financial Results and Business Highlights
TORRANCE, Calif., Nov. 12, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported ...
Emmaus Life Sciences Announces Partnership with UpScript to Provide Telehealth Solutions to Sickle Cell Disease Patients
TORRANCE, Calif., Nov. 11, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA) a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced ...
Emmaus Life Sciences to Participate in the Q4 Virtual Investor Summit
Torrance, California--(Newsfile Corp. - November 8, 2021) - Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, tod...
Emmaus Life Sciences Enters into Agreement with Asembia to Provide Expanded Patient Support Services
TORRANCE, Calif. , Nov. 4, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced...
Emmaus Life Sciences Submits Application for U.A.E. Marketing Authorization for Endari®
TORRANCE, Calif., Oct. 26, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA) a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced th...
Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos Medicine
TORRANCE, Calif., Oct. 12, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced...
OTC Markets Group Welcomes Emmaus Life Sciences, Inc. to OTCQX
NEW YORK, Sept. 8, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced Emmaus Life Sciences, Inc. (OTCQX: EMMA...
3 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overa...
Emmaus Life Sciences Reports Financial Results for the Six Months Ended June 30, 2021
TORRANCE, Calif., Sept. 2, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced f...
Emmaus Life Sciences Announces Bahrain Temporary License of Endari®
TORRANCE, Calif. , Aug. 17, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today ...
Emmaus Life Sciences Provides SEC Reporting Update
TORRANCE, Calif., Aug. 10, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in sickle cell disease treatment, announced today that it has restated its financial statements for the f...
Texas Adds Endari® to Latest Preferred Drug List
TORRANCE, Calif., Aug. 2, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in the treatment of sickle cell disease, announced today that Endari® has been included on the Preferred D...
Emmaus Life Sciences Provides Interim Sales Information
TORRANCE, Calif., July 22, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in sickle cell disease treatment, announced today preliminary sales results for the six months ended June...